Organogenesis (NASDAQ:ORGO – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
Profitability
This table compares Organogenesis and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Organogenesis | -39.34% | -55.28% | -23.72% |
| Connect Biopharma | N/A | -165.41% | -121.58% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Organogenesis and Connect Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Organogenesis | 1 | 2 | 0 | 0 | 1.67 |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
Organogenesis presently has a consensus price target of $4.33, suggesting a potential upside of 439.58%. Connect Biopharma has a consensus price target of $5.88, suggesting a potential upside of 813.69%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Organogenesis.
Risk and Volatility
Organogenesis has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
Valuation and Earnings
This table compares Organogenesis and Connect Biopharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Organogenesis | $564.17 million | 0.18 | $37.03 million | ($1.22) | -0.66 |
| Connect Biopharma | $60,000.00 | 674.83 | -$55.48 million | ($1.19) | -0.54 |
Organogenesis has higher revenue and earnings than Connect Biopharma. Organogenesis is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Connect Biopharma beats Organogenesis on 8 of the 13 factors compared between the two stocks.
About Organogenesis
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.
About Connect Biopharma
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
